23,199 Shares in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Purchased by Verition Fund Management LLC

Verition Fund Management LLC acquired a new position in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 23,199 shares of the company's stock, valued at approximately $763,000. Verition Fund Management LLC owned 0.06% of Tarsus Pharmaceuticals at the end of the most recent quarter.

Other hedge funds also recently bought and sold shares of the company. Quest Partners LLC acquired a new position in shares of Tarsus Pharmaceuticals during the 2nd quarter worth about $61,000. Canada Pension Plan Investment Board bought a new position in Tarsus Pharmaceuticals in the 2nd quarter worth approximately $114,000. FMR LLC lifted its holdings in shares of Tarsus Pharmaceuticals by 236.6% during the third quarter. FMR LLC now owns 5,032 shares of the company's stock worth $166,000 after buying an additional 3,537 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in shares of Tarsus Pharmaceuticals by 33.4% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 6,109 shares of the company's stock valued at $166,000 after acquiring an additional 1,530 shares during the period. Finally, SG Americas Securities LLC grew its stake in shares of Tarsus Pharmaceuticals by 87.5% in the third quarter. SG Americas Securities LLC now owns 7,242 shares of the company's stock worth $238,000 after acquiring an additional 3,379 shares during the last quarter. 90.01% of the stock is currently owned by institutional investors.

Tarsus Pharmaceuticals Price Performance

Shares of TARS stock traded down $0.01 during mid-day trading on Tuesday, reaching $50.65. The company's stock had a trading volume of 763,368 shares, compared to its average volume of 713,825. The firm's 50-day moving average is $43.22 and its two-hundred day moving average is $33.90. The company has a market cap of $1.94 billion, a P/E ratio of -13.30 and a beta of 1.04. Tarsus Pharmaceuticals, Inc. has a 1-year low of $16.75 and a 1-year high of $52.99. The company has a debt-to-equity ratio of 0.30, a quick ratio of 5.38 and a current ratio of 5.42.

Analyst Ratings Changes

TARS has been the subject of several research analyst reports. Oppenheimer upped their target price on shares of Tarsus Pharmaceuticals from $63.00 to $65.00 and gave the company an "outperform" rating in a research note on Thursday, November 14th. The Goldman Sachs Group boosted their price objective on shares of Tarsus Pharmaceuticals from $36.00 to $41.00 and gave the stock a "neutral" rating in a report on Friday, November 15th. Finally, William Blair upgraded shares of Tarsus Pharmaceuticals to a "strong-buy" rating in a research note on Friday, August 30th. One research analyst has rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat, the company presently has a consensus rating of "Buy" and an average target price of $54.20.

Tarsus Pharmaceuticals Company Profile

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.